期刊文献+

坎地沙坦酯与拉西地平联合应用对高血压患者蛋白尿的影响 被引量:8

原文传递
导出
摘要 目的观察坎地沙坦酯与拉西地平合用对高血压患者蛋白尿的影响。方法将高血压合并蛋白尿的患者90例随机分为:坎地沙坦酯4mg/d+拉西地平4mg/d(A组)或拉西地平4mg/d+氢氯噻嗪12.5mg/d(B组),治疗6月。观察治疗前后血压、24h尿白蛋白总量、尿素氮、血肌酐的变化。结果治疗6月后,A、B两组血压较治疗前明显下降(P<0.01),但两组之间差异无统计学意义(P>0.05)。A、B两组尿蛋白均可下降,但A组较B组下降更明显(P<0.01),A组降低尿素氮、肌酐更显著(P<0.01)。结论坎地沙坦酯与拉西地平联合应用能平稳降压,显著降低尿蛋白的排泄,保护肾脏功能。
出处 《中华高血压杂志》 CAS CSCD 北大核心 2010年第11期1085-1087,共3页 Chinese Journal of Hypertension
  • 相关文献

参考文献9

  • 1Abbate M, Zoja D, Rotteli D, et al. Antiproteinurlc therapy while preventing the abnormal protein trafic inproximal tubule abrogates protein and complement-dependant interstital inflam marion in experimental renal disease[J]. J Am Soc Nephml, 1999, 10(7):804-813.
  • 2柏原直树,任常陵.合并肾损害的高血压的治疗[J].日本医学介绍,2003,24(3):136-137. 被引量:3
  • 3黄绍湘,杨小英,卢幻真,解蓓.坎地沙坦酯与左旋氨氯地平合用对原发性高血压微量蛋白尿的影响[J].中国现代药物应用,2008,2(10):40-41. 被引量:11
  • 4Remuzzi A, Perticucci E, Reggenenti P, et al. Angiotensin con- verting enzyme inhibition improve glomarular size-selectivity in IgA nephropathy[J]. Kidney Int,1991,39(6) : 1267-1273.
  • 5Woo KT, Lau YK, Wong KS, et al. ACEI/ATRA therapy de- creases proteinuria by improving glomerular permselectivity in IgA nephritis[J]. Kidney Int, 2000,58(6) : 2485-2491.
  • 6Keane WF, Brenner BM, de Zeeuw D, et al. The risk of develo- ping end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study[J]. Kidney Int, 2003,63 (4) : 1499-1507.
  • 7Fukui T, Rahman M, Morita S, et al. Informed consent in the candesartan antihypertensive survival evaluation in Japan (CASE- J) trial: a survey of collaborating pbysicians[J]. Hypertens Res, 2006,29(7) :471-474.
  • 8阮昱.糖尿病肾病的治疗进展[J].中国实用内科杂志,2003,23(1):58-59. 被引量:45
  • 9Hasebe N. NICE-Combistudy: effect of nifedipinein combination with an angiotensin Ⅱ receptor blocker on BP control and renal protection[J]. Drugs,2006,66(1):16-18.

二级参考文献21

  • 1高血压病人预后的一个可靠指标——尿微量白蛋白[J].高血压杂志,2006,14(2):82-83. 被引量:4
  • 2尹学亮,李建柱,梁添书,张启确,曾文坦.辛伐他汀对原发性高血压患者血、尿β_2-微球蛋白的影响[J].临床内科杂志,2007,24(1):52-53. 被引量:9
  • 3[1]Rekha S,Nahid A,Ashok K,et al.Role of angiotensin Ⅱin glucose-induced inhibition of mesangial matrix degradation.Diabetes,1999,48(10):2066
  • 4[2]Hollenberg NK.ACE inhibior,AT1 receptor blockers,and kidney.Nephrol Dial Transp,1997,12:381
  • 5[3]Rajiv A.Add-on angiotensin receptor blockade with maximized ACE inhibition.Kidney Int,2001,59:2282
  • 6[4]Karin JD,Zemin C,Alison J.Role of hyperlipidemia in progressive renal disease:focus on diabetic nephropathy.Kidney Int,1999,56(suppl71):S31
  • 7[5]Hung CC,Jinn YG,Shyi JS,et al.Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with low-density lipoprotein.Kidney Int,2001,59(suppl):S124
  • 8[6]Park YS,Gudarro C,Kim Y,et al.Lovasatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats.Am J Kidney Dis,1998,31:190
  • 9[7]Tamotsu Y,Kazunori U,Yuichi M,et al.Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.Kidney Int,1999,56(suppl71):S178
  • 10[8]Antonio C,Anna M,Franceschina M,et al.Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy.Diabetes,2000,49:2170

共引文献55

同被引文献45

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部